It is recommended that you also refer to as the Summary of Product Characteristics may have been updated since this copy was printed.

Flynn Pharma Ltd

Flynn Pharma Ltd

Summary of Product Characteristics last updated on 12/3/2018

Distaclor 125mg/5ml Granules for Oral Suspension


Distaclor 125 mg/5 ml Granules for Oral Suspension.


Cefaclor (as monohydrate), 125 mg/5 ml.

Excipient: sucrose 3 g/5 ml

For a full list of excipients, see section 6.1


Granules for oral suspension.

A dry pink, free-flowing, granular powder, which on reconstitution with water gives a pink coloured, strawberry flavoured suspension.


4.1 Therapeutic indications

Distaclor is indicated for the treatment of the following infections due to susceptible micro-organisms:

Respiratory tract infections, including pneumonia, bronchitis, exacerbations of chronic bronchitis, pharyngitis and tonsillitis, and as part of the management of sinusitis.

Otitis media

Skin and soft tissue infections

Urinary tract infections, including pyelonephritis and cystitis.

Distaclor has been found to be effective in both acute and chronic urinary tract infections.

Cefaclor is generally effective in the eradication of streptococci from the nasopharynx, however, data establishing efficacy in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available.

4.2 Posology and method of administration


Adults (including the elderly):

The usual adult dosage is 250mg every eight hours. A dosage of 250mg, administered 3 times daily for 10 days, is recommended for sinusitis. For more severe infections or those caused by less susceptible organisms, doses may be doubled.

Doses of 4g per day have been administered safely to normal subjects for 28 days, but the total daily dosage should not exceed this amount.


The usual recommended daily dose for children is 20mg/kg/day, in divided doses, every eight hours, as indicated. For bronchitis and pneumonia, the dosage is 20mg/kg/day in divided doses, administered 3 times daily. For otitis media and pharyngitis, the total daily dosage may be divided and administered every 12 hours. Safety and efficacy have not been established for use in infants aged less than one month. Suggested doses for children are:-

Distaclor Suspension



<1 year (9kg)

2.5ml tid

1-5 years (9-18kg)

5.0ml tid

Over 5 years

5.0ml tid

In more serious infections, otitis media and infections caused by less susceptible organisms, 40mg/kg/day, in divided doses is recommended, up to a daily maximum of 1g.

In the treatment of beta-haemolytic streptococcal infections, therapy should be continued for at least 10 days.

Patients with impaired renal function:

Cefaclor may be administered in the presence of impaired renal function. Under such conditions, dosage is unchanged. Cefaclor should be administered with caution in the presence of markedly impaired renal function. Since the half-life of cefaclor in anuric patients is 2.3 to 2.8 hours (compared to 0.6 to 0.9 hours in normal subjects), dosage adjustments for patients with moderate or severe renal impairment are not usually required. Clinical experience with cefaclor under such conditions is limited; therefore, careful clinical observation and laboratory studies should be made.

Patients undergoing haemodialysis:

Haemodialysis shortens serum half-life by 25-30%. In patients undergoing regular haemodialysis, a loading dose of 250mg-1g, administered prior to dialysis, and a therapeutic dose of 250-500mg every six to eight hours maintained during interdialytic periods is recommended.

Method of administration

Distaclor is administered orally.

4.3 Contraindications

Hypersensitivity to cephalosporins.

4.4 Special warnings and precautions for use


Before instituting therapy with cefaclor, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to cefaclor, cephalosporins, penicillins or other drugs. Cefaclor should be given cautiously to penicillin-sensitive patients because cross-hypersensitivity, including anaphylaxis, among beta-lactam antibiotics has been clearly documented.

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

If an allergic reaction to cefaclor occurs, the drug should be discontinued and the patient treated with the appropriate agents.

Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semi-synthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.


Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastro-intestinal disease, particularly colitis.

Prolonged use of cefaclor may result in the overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies or in transfusion cross-matching procedures, when anti-globulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.

A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.

Cross-resistance may exist between penicillins and cephalosporins.

4.5 Interaction with other medicinal products and other forms of interaction

There have been rare reports of increased prothrombin time, with or without clinical bleeding, in patients receiving cefaclor and warfarin concomitantly. It is recommended that in such patients, regular monitoring of prothrombin time should be considered, with adjustment of dosage if necessary.

The renal excretion of cefaclor is inhibited by probenecid.

4.6 Fertility, pregnancy and lactation


Cefaclor should not be administered during pregnancy unless considered essential by the physician. Animal studies have shown no evidence of impaired fertility or teratogenicity. However, there are no adequate and well-controlled studies in pregnant women.


Small amounts of cefaclor have been detected in breast milk following administration of single 500mg doses. Average levels of about 0.2 micrograms/ml or less were detected up to 5 hours later. Trace amounts were detected at one hour. As the effect on nursing infants is not known, caution should be exercised when cefaclor is administered to a nursing woman.

4.7 Effects on ability to drive and use machines

Distaclor has no known influence on the ability to drive and use machines.

4.8 Undesirable effects


The most frequent side-effect has been diarrhoea. It is rarely severe enough to warrant cessation of therapy. Colitis, including rare instances of pseudomembranous colitis, has been reported. Nausea and vomiting have also occurred.


Allergic reactions, such as morbilliform eruptions, pruritus and urticaria, have been observed. These reactions usually subside upon discontinuation of therapy. Serum sickness-like reactions (erythema multiforme minor, rashes or other skin manifestations accompanied by arthritis/arthralgia, with or without fever) have been reported. Lymphadenopathy and proteinuria are infrequent; there are no circulating immune complexes and no evidence of sequelae. Occasionally, solitary symptoms may occur, but do not represent a serum sickness-like reaction. Serum sickness-like reactions are apparently due to hypersensitivity and have usually occurred during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in children than in adults. Signs and symptoms usually occur a few days after initiation of therapy and usually subside within a few days of cessation of therapy.

Antihistamines and corticosteroids appear to enhance resolution of the syndrome. No serious sequelae have been reported.

There are rare reports of erythema multiforme major (Stevens-Johnson syndrome), toxic epidermal necrolysis and anaphylaxis. Anaphylaxis may be more common in patients with a history of penicillin allergy. Anaphylactoid events may present as solitary symptoms, including angioedema, asthenia, oedema (including face and limbs), dyspnoea, paraesthesias, syncope, or vasodilatation.

Rarely, hypersensitivity symptoms may persist for several months.


Eosinophilia, positive Coombs' tests and, rarely, thrombocytopenia. Transient lymphocytosis, leucopenia and, rarely, haemolytic anaemia, aplastic anaemia, agranulocytosis and reversible neutropenia of possible clinical significance. See 'Drug Interactions'.


Transient hepatitis and cholestatic jaundice have been reported rarely, slight elevations in AST, ALT or alkaline phosphatase values.


Reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.

Central nervous system:

Reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely.


Genital pruritus, vaginitis and vaginal moniliasis.

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

HPRA Pharmacovigilance

Earlsfort Terrace

IRL - Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517



4.9 Overdose

Symptoms of nausea, vomiting, epigastric distress and diarrhoea would be anticipated.


Unless 5 times the normal total daily dose has been ingested, gastro-intestinal decontamination will not be necessary.

General management may consist of supportive therapy.


5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Second generation cephalosporins, ATC code: J01DC04

Cefaclor is a semi-synthetic cephalosporin antibiotic. The bacterial action of the cephalosporins results from their inhibition of cell-wall synthesis.

Cefaclor is active against the following organisms in vitro: Alpha- and beta-haemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative and penicillinase-producing strains; Streptococcus pyogenes; Str. Pneumoniae penicillin-sensitive strains; Branhamella catarrhalis; Escherichia coli; Proteus mirabilis; Klebsiella spp.; Haemophilus influenzae, including beta-lactamase-producing strains.

Cefaclor has no activity against Pseudomonas spp. or Acinetobacter spp. Methicillin-resistant staphylococci and most strains of enterococci (eg, Str. faecalis) and penicillin-resistant Str. Pneumoniae are resistant to cefaclor. Cefaclor is not active against most strains of Enterobacter spp., Serratia spp., Morganella morganii, Proteus vulgaris and Providencia rettgeri. The rare beta-lactamase-negative, ampicillin-resistant H. influenzae should be considered resistant to cefaclor.

5.2 Pharmacokinetic properties

Cefaclor is well absorbed after oral administration in fasting subjects. Total absorption is unchanged in the presence of food, however, peak plasma levels are reduced by about half and the peak is delayed. Following administration of 250mg, 500mg and 1g to fasting subjects, average peak plasma concentration of 7, 13 and 23mg/l, respectively were obtained within 30 to 60 minutes. The serum half-life in normal subjects is 0.6 to 0.9 hour. Probenecid significantly prolongs the half-life. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours. Haemodialysis shortens the half-life by 25-30%. Cefaclor is about 50% bound to plasma proteins. The drug is rapidly excreted by the kidneys; up to 85% appears unchanged in the urine within 8 hours, the greater part within 2 hours. During this 8 hour period, peak urine concentrations following 250mg, 500mg and 1g doses were about 600, 900 and 1900mg/l, respectively.

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber in addition to that summarised in other sections of the Summary of Product Characteristics.


6.1 List of excipients


Erythrosine Aluminium Lake (E127)

Methylcellulose 15

Sodium laurilsulfate (E487)

Artificial strawberry flavour (includes dextrins (E1400), ethyl citrate, propylene glycol (E1520))

Xanthan gum (E415)

Pregelatinised starch


6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Dry granules:

2 years.

Reconstituted granules:

14 days

6.4 Special precautions for storage

Dry granules:

Do not store above 25°C. Store in original container.

Reconstituted granules:

Store between 2°C - 8°C.

6.5 Nature and contents of container

The product is packaged in either HDPE bottles of 100ml with plastic screw caps or in sachets with laminate of paper/polythene/aluminium foil/polythene.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

The product contained in bottles should be shaken both before and after reconstitution. To reconstitute, the pharmacist should add a total of 60ml of water in two portions, shaking after each addition until suspended. Where dilution is unavoidable, Syrup BP should be used after the suspension has been prepared as described.

To reconstitute the product contained in sachets, the doctor/patient should empty the contents of one sachet into a glass and then add 4 x 5ml spoonfuls of water and stir well.

Any unused product should be returned to the pharmacist for safe disposal.


Flynn Pharma Limited

Marine House

Clanwilliam Place

Dublin 2



PA 1226/1/2


Date of first authorisation: 16 November 1998

Date of last renewal: 16 June 2008


9 March 2018

It is recommended that you also refer to as the Summary of Product Characteristics may have been updated since this copy was printed.